While the focus is primarily on immune checkpoints like the programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4), scarce clinical trials conducted on ICIs for gliomas have yielded significant outcomes [12–14]. The gene discussed is CTLA4; the disease is glioma.